Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Prelude Therapeutics

Request full access

The discovery and development of novel, small molecule therapies to treat cancer

Wilmington, United StatesFounded 2016Biotech & Life Sciences

About Prelude Therapeutics

Prelude Therapeutics, a clinical-stage precision oncology company, was established in Wilmington, Delaware, in 2016 by founder and CEO Dr. Kris Vaddi. Dr. Vaddi, a founding scientist at Incyte Corp, leveraged his extensive experience, including his role in developing approved drugs like Jakafi®, to create a company focused on developing targeted cancer therapies. The company began with $5 million in seed funding at the University of Delaware STAR Campus before moving to the Delaware Innovation Space.

The company operates within the competitive oncology market, focusing on the discovery and development of small molecule drugs that target key driver mechanisms in cancers with high unmet medical needs. As a clinical-stage biopharmaceutical firm, Prelude does not yet have approved products for sale and its revenue is primarily derived from collaboration agreements. The company's financial strategy has included several funding rounds, starting with a Series A of $20 million in 2016 and culminating in a successful Initial Public Offering (IPO) in September 2020, which raised approximately $181.9 million after underwriters fully exercised their option to purchase additional shares. A subsequent public offering in May 2023 was expected to generate gross proceeds of around $100 million.

Prelude's core business involves identifying and validating promising drug targets within cancer cell signaling pathways to develop differentiated, and potentially best-in-class, therapies. Its diverse pipeline includes several novel drug candidates. A key area of focus is on protein degradation, featuring first-in-class SMARCA2 protein degraders and KAT6A selective degraders. The oral SMARCA2 degrader, PRT7732, is currently in clinical trials with preliminary data expected by the end of 2025. To concentrate resources on this promising oral candidate, development of the intravenous SMARCA2 degrader, PRT3789, has been paused. The company is also advancing its oral KAT6A degrader program, with plans to file an Investigational New Drug (IND) application in the first half of 2026. Furthermore, Prelude is developing next-generation degrader antibody conjugates (ADCs) through strategic partnerships with companies like AbCellera and Merck, aiming to deliver targeted drug payloads to cancer cells.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
Wilmington, United States
Employees
107
Open positions
1
Dealroom signal
28.1/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
PRIVATE PLACEMENT VCOther financing Apr 2026 $90M — RA Capital Management ↗
PRIVATE PLACEMENT NON VCOther financing Nov 2025 $25M — Undisclosed ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026
2025
2024 —
2023 — —
2022 — —
2021 — —
2020 — —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Prelude Therapeutics website traffic

Latest recorded traffic for Prelude Therapeutics is 6.8K monthly website visits, down 4.2% over the last three months. Prelude Therapeutics's team declined 13% over the past year.

Latest monthly visits6.8K 3-month web change-4.2% 1-year team growth-13%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Prelude Therapeutics in the Wilmington ecosystem

Live from Dealroom

The Prelude Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Series B and later1 investor entered at this stage

Other known investors1 additional known investor

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Prelude Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Prelude Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.